Aspira Women’s Health 

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Aspira Women's Health (AWH) sees robust growth and innovation in Q1 2024

Aspira Women's Health (AWH) reported strong performance in Q1 2024, driven by significant growth in test volumes and improvements in financial metrics. The company's focus on innovation and collaboration underscores its commitment to advancing women's health diagnostics. While challenges in funding persist, AWH's strategic initiatives and market opportunities position it for continued growth and success in the future.

Aspira Women's Health achieves record test volumes amidst cost challenges

AWH reported strong performance in test volumes and revenue growth in Q2 2024.
While facing challenges with margins and costs, the company is actively addressing them.
Opportunities lie in product development, market expansion, and cost control measures.
Overall, AWH is strategically positioned for growth and innovation in the women's health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, today announced it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aspira is expected to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock being offered at the public offering price, less underwriting discounts and commissions. All of the shares will be offered by Aspira.

Aspira Women's Health Inc. Announces Proposed Public Offering of Common Stock

Fulgent Genetics

GenMark Diagnostics

Natera

Co-Diagnostics

These winners are positioned for gains even after COVID.

These Were the 5 Best Diagnostics Stocks of 2020

Aspira to participate in the 10 th Annual LifeSci Advisors Corporate Access Event and  Biotech Showcase™ from January 6 – 15 th , 2021

Aspira Women's Health, Inc. to Participate in Virtual Investor Events

News for Aspira Women’s Health Stock (AWH)